Lucid Diagnostics
LUCD
Lucid Diagnostics
Energy Small Cap Updated Feb 6, 2026

Lucid pulled in $4M of annual revenue with a $179M market cap attached to it.

If you own LUCD, you need to know how tiny the sales base is.

$1.23
Market cap ~$179M · 52-week range $1–$2
26
Composite
Our overall rating — combines growth, value, risk, and momentum
XVARY Composite Score
26
/ 100

Weak

Combines growth, value, risk, and momentum factors into a single institutional-grade score.

Start here if you're new
What it is
Lucid sells a swallowable device and DNA test that screen GERD patients for esophageal precancer.
How it gets paid
Last year Lucid Diagnostics made $4M in revenue. EsoGuard testing was the main engine at $2.0M, or 50% of sales.
What just happened
Revenue hit $3M, but EPS landed at -$0.59.
At a Glance
C++ balance sheet — some cracks in the foundation
-$1.05 fy2024 eps est
$2B fy2026 rev est
N/a operating margin
1.1 beta
XVARY composite: 26/100 — weak
What They Do
Lucid sells a swallowable device and DNA test that screen GERD patients for esophageal precancer.
The moat is not a patent castle. It is a workflow wall. EsoCheck is FDA 510(k)-cleared and CE Mark-cleared, and Lucid has 72 employees pushing one narrow job. You do not rip out a swallowable capsule and a DNA assay once your clinic builds them into screening.
healthcare micro-cap diagnostics screening medtech
How They Make Money
$4M annual revenue
EsoGuard testing
$2.0M
EsoCheck devices
$1.0M
VA and health-system contracts
$0.7M
Other revenue
$0.3M
The Products That Matter
DNA test for precancer
EsoGuard
$3.2M · 80% of revenue shown
It's the main commercial product, generating $3.2M of the $4.0M revenue shown here. If reimbursement expands, this is where the upside has to appear.
core thesis
Cell collection device
EsoCheck
$0.8M · 20% of revenue shown
This is the disposable collection device tied to the test. It brought in $0.8M, which means the company is still monetizing the workflow at a very small scale.
paired with testing
Key Numbers
$4M
annual revenue
This is the whole business in one line. You are looking at a company with $4M of sales and a much bigger market cap attached to it.
$3M
latest quarter
One quarter delivered most of the year's sales. That is a lumpy setup, not a smooth one.
n/a
operating margin
Prior margin KPI failed sanity check — verify in filings. Lucid spent about $10.60 for every $1 of sales. That is what cash burn looks like in plain English.
$1M
debt
Long-term debt is light at $1M, or 1% of capital. The problem is not leverage. The problem is the tiny revenue base.
Financial Health
C++
Strength
  • balance sheet grade C++ — below average — limited financial resources
  • risk rank 5 — safer than 5% of stocks
  • price stability 5 / 100
  • long-term debt $1M (1% of capital)
C++ — below average. watch for debt servicing and cash burn.
Total Return vs. Market

same standard. no invented return math.

source: institutional data · return history unavailable
What Just Happened
missed estimates
Revenue hit $3M, but EPS landed at -$0.59.
Sales were up 164% from a year earlier. The company still posted a loss while it pushes adoption and reimbursement.
$3M
revenue
$0.59
eps
164%
revenue growth
the number that mattered
The 164% jump says the business is finding traction. The -$0.59 EPS says the cash drain is still there.
source: company earnings report, 2026

Get this snapshot in your inbox

This page, delivered free — plus weekly updates when the numbers change. Plain English, no spam.

Weekly updates Earnings alerts Plain English No spam
What Could Go Wrong

The #1 risk is Medicare refusing or delaying nationwide coverage for EsoGuard. This is a reimbursement story first and a commercial story second.

!
High
Medicare coverage denial or delay
The bull case depends on a National Coverage Determination for EsoGuard. In plain English: Medicare deciding to pay for the test nationwide. If that slips or fails, the current $1.2M quarterly revenue base has to carry the story on its own, and it clearly cannot.
The bull case depends on a National Coverage Determination for EsoGuard. In plain English: Medicare deciding to pay for the test nationwide. If that slips or fails, the current $1.2M quarterly revenue base has to carry the story on its own, and it clearly cannot.
!
High
Cash burn and dilution
A $10.4M quarterly GAAP net loss on $1.2M of revenue points to more financing risk. The 21% after-hours drop tied to a december 2025 financing headline is what that looks like in real time.
A $10.4M quarterly GAAP net loss on $1.2M of revenue points to more financing risk. The 21% after-hours drop tied to a december 2025 financing headline is what that looks like in real time.
∘
Med
Commercial adoption still looks early
Revenue grew 3.3% from last year in Q3 2025. That's better than decline, but it is nowhere near the ramp you'd want to see before underwriting a much bigger diagnostics platform.
Revenue grew 3.3% from last year in Q3 2025. That's better than decline, but it is nowhere near the ramp you'd want to see before underwriting a much bigger diagnostics platform.
∘
Med
Single-product concentration
EsoGuard generated $3.2M of the $4.0M revenue shown here. When one product carries almost the whole business, any reimbursement, adoption, or clinical credibility issue hits the company all at once.
EsoGuard generated $3.2M of the $4.0M revenue shown here. When one product carries almost the whole business, any reimbursement, adoption, or clinical credibility issue hits the company all at once.
A reimbursement setback would pressure nearly all of the commercial story, while the current loss profile already points toward more external funding if growth does not inflect.
Source: institutional data · regulatory filings · risk analysis
Pay Attention To
Catalyst
Medicare coverage decision
This is the whole ballgame. A National Coverage Determination would answer whether Medicare will reimburse EsoGuard nationwide.
Calendar
Q4 and full-year 2025 earnings call
Scheduled for mar 26, 2026. Listen for cash runway commentary, reimbursement timing, and whether the VA contract has turned into revenue.
Trend
Revenue growth above 3.3%
Quarterly revenue growth of 3.3% from last year is not enough to change the narrative. You want to see a real adoption curve, not incremental movement.
Metric
Losses versus revenue
The current ratio is brutal: $10.4M lost on $1.2M of revenue. Any quarter that narrows that gap meaningfully would matter more than polished press releases.
Analyst Rankings
coverage depth
thin
Consensus data is limited. In human-speak, there is not enough broad analyst coverage here to treat Wall Street as a safety blanket.
composite score
26 / 100
That puts LUCD in weak territory. Translation: the market sees more execution risk than operating proof right now.
beta
1.1
Beta measures how much a stock tends to move with the market. At 1.1, LUCD is not wildly disconnected from the tape — but its company-specific risk still dominates the story.
Source: institutional data
Institutional Activity

institutional ownership data for LUCD is being compiled.

source: institutional data
Source: institutional data
Price Targets
3-5 year target range
$1 Current price
Target midpoint · from current
target data not available

Want the deeper analysis?

The full deep dive: DCF model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.

See plans from $5/mo
The Deep Dive
LUCD
XVARY Deep Dive
lucd
The full analysis is in the works.
What you'll get
DCF valuation model
Bull / base / bear scenarios
Competitive moat breakdown
Quarterly earnings tracker
Operating model projections
Risk matrix with kill criteria
Original price target + conviction
Updated with every earnings
Free · no spam · you'll be first to read it